Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.01 +1.3%	$8.23	$6.38 ▼ $17.30	$859.03M	1.4	1.23 million shs	1.07 million shs
PTCT PTC Therapeutics	$46.01 +1.5%	$48.22	$28.72 ▼ $58.38	$3.65B	0.52	870,808 shs	1.56 million shs
RNA Avidity Biosciences	$30.35 +4.8%	$29.22	$21.51 ▼ $56.00	$3.49B	1	1.44 million shs	1.34 million shs
SRPT Sarepta Therapeutics	$36.43 +3.3%	$60.11	$34.10 ▼ $173.25	$3.47B	0.85	1.71 million shs	4.04 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	-4.05%	+12.20%	+4.65%	-44.00%
PTCT PTC Therapeutics	0.00%	+4.02%	-2.91%	-11.21%	+36.69%
RNA Avidity Biosciences	0.00%	+8.90%	+13.84%	-6.07%	+2.85%
SRPT Sarepta Therapeutics	0.00%	+0.44%	-32.27%	-66.25%	-72.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.0273 of 5 stars	3.5	1.0	0.0	2.6	1.7	0.6
PTCT PTC Therapeutics	4.2885 of 5 stars	4.3	3.0	4.4	2.6	0.8	0.0
RNA Avidity Biosciences	2.5592 of 5 stars	4.5	2.0	0.0	2.5	0.8	0.0
SRPT Sarepta Therapeutics	4.7772 of 5 stars	4.4	2.0	4.2	2.6	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$19.43	115.63% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$61.92	34.59% Upside
RNA Avidity Biosciences	3.00	Buy	$66.38	118.73% Upside
SRPT Sarepta Therapeutics	2.82	Moderate Buy	$124.36	241.38% Upside

Current Analyst Ratings Breakdown

Latest AVDL, PTCT, SRPT, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$72.00 ➝ $68.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/8/2025	SRPT Sarepta Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$188.00 ➝ $85.00
5/8/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$115.00 ➝ $100.00
5/8/2025	SRPT Sarepta Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$50.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00
5/7/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$113.00 ➝ $112.00
5/7/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $67.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$194.45M	4.48	N/A	N/A	$0.98 per share	9.19
PTCT PTC Therapeutics	$1.77B	2.06	$2.21 per share	20.80	($10.85) per share	-4.24
RNA Avidity Biosciences	$8.93M	409.74	N/A	N/A	$6.76 per share	4.49
SRPT Sarepta Therapeutics	$2.23B	1.60	N/A	N/A	$9.19 per share	3.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$0.27	N/A	150.17	N/A	-52.53%	-93.34%	-44.77%	N/A
PTCT PTC Therapeutics	-$626.60M	$6.51	N/A	N/A	N/A	-50.32%	N/A	-16.44%	N/A
RNA Avidity Biosciences	-$212.22M	-$3.00	N/A	N/A	N/A	-2,772.45%	-27.66%	-24.56%	N/A
SRPT Sarepta Therapeutics	-$535.98M	-$2.69	29.14	3.33	N/A	7.43%	11.00%	3.35%	N/A

Latest AVDL, PTCT, SRPT, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
2/27/2025	Q4 2024	RNA Avidity Biosciences	-$0.76	-$0.80	-$0.04	-$0.80	$1.74 million	$2.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.97	2.60
PTCT PTC Therapeutics	N/A	2.10	2.04
RNA Avidity Biosciences	N/A	17.76	17.76
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
PTCT PTC Therapeutics	N/A
RNA Avidity Biosciences	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
PTCT PTC Therapeutics	5.50%
RNA Avidity Biosciences	3.83%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.63 million	91.74 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	72.88 million	Optionable
RNA Avidity Biosciences	190	120.52 million	114.92 million	Optionable
SRPT Sarepta Therapeutics	840	98.28 million	88.17 million	Optionable

AVDL, PTCT, SRPT, and RNA Headlines

Recent News About These Companies

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

May 16 at 7:24 PM | finance.yahoo.com

Novartis, Sarepta tipped to drive genomic therapy sales toward $90B

May 15 at 5:46 PM | fiercepharma.com

Orbimed Advisors LLC Sells 41,100 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 15 at 7:44 AM | marketbeat.com

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates

May 14, 2025 | finance.yahoo.com

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore (SRPT)

May 14, 2025 | marketbeat.com

Ensign Peak Advisors Inc Has $21.10 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 14, 2025 | marketbeat.com

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

May 13, 2025 | finance.yahoo.com

J. Goldman & Co LP Purchases 8,628 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 13, 2025 | marketbeat.com

Janus Henderson Group PLC Sells 30,188 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 13, 2025 | marketbeat.com

2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying

May 13, 2025 | fool.com

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

May 12, 2025 | finance.yahoo.com

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

May 11, 2025 | insidermonkey.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Lifted by Farallon Capital Management LLC

May 11, 2025 | marketbeat.com

Bokf Na Acquires 11,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 11, 2025 | marketbeat.com

Stifel Financial Corp Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 11, 2025 | marketbeat.com

Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 11, 2025 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Evercore ISI

May 10, 2025 | marketbeat.com

Fred Alger Management LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 10, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

May 10, 2025 | accessnewswire.com

Why Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Up 6.43%

May 10, 2025 | aaii.com

Balyasny Asset Management L.P. Sells 218,359 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

May 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVDL, PTCT, SRPT, and RNA Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.01 +0.12 (+1.35%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$9.23 +0.22 (+2.44%)

As of 05/16/2025 05:10 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

PTC Therapeutics NASDAQ:PTCT

$46.01 +0.70 (+1.54%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$46.02 +0.02 (+0.03%)

As of 05/16/2025 05:10 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Avidity Biosciences NASDAQ:RNA

$30.35 +1.38 (+4.76%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$29.61 -0.74 (-2.43%)

As of 05/16/2025 07:27 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Sarepta Therapeutics NASDAQ:SRPT

$36.43 +1.16 (+3.29%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$36.10 -0.33 (-0.89%)

As of 05/16/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time